ADAC brings PET to oncologists
ADAC Laboratories and American Diagnostic Medicine have signed an agreement with the International Oncology Network to offer PET imaging services to the network's 2000 oncologists. This agreement is an offshoot of the "First Nuclear" joint venture
ADAC Laboratories and American Diagnostic Medicine have signed an agreement with the International Oncology Network to offer PET imaging services to the network's 2000 oncologists. This agreement is an offshoot of the "First Nuclear" joint venture between ADAC and ADM.
Any International Oncology Network member can sign up for the First Nuclear program. ADAC will provide the PET scanners and trained technologists to perform diagnostic exams, along with supplies, marketing, state licensing, procedure coding, and other information. ADM will provide the facilities and administrative services.
ADAC has been developing PET scanners for five years. Three years ago, the company introduced C-PET, a dedicated whole-body scanning device. ADM runs programs that let hospitals, freestanding clinics, group practices, and other managed-care providers deliver medical imaging services.
Also this month, ADAC announced results of its second quarter 2000. Revenue was $90 million compared to $87.4 million for second quarter 1999. The company's net income for the quarter was $3.1 million compared to a net loss of $7.9 million in second quarter 1999. ADAC said the second quarter 1999 loss was due to combined pretax restructuring and pretax charges of $18 million.
ADAC received orders for 16 C-PET units during the second quarter of fiscal 2000, compared with orders for 10 units in the first quarter.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
